Tag Archives: respiratory and inflammation pipeline

GSK Strengthens Immunology Pipeline with $2.2 Billion RAPT Therapeutics Acquisition

(IN BRIEF) GSK has agreed to acquire RAPT Therapeutics in a transaction valued at approximately $2.2 billion, adding ozureprubart, a phase IIb long-acting anti-IgE antibody for food allergy prevention, to its Respiratory, Immunology & Inflammation pipeline. Designed to offer sustained … Read the full press release